Calidi Biotherapeutics Soars 119.7% on Cancer Trial News

On July 9, 2025, Calidi Biotherapeutics Inc. (NYSE American: CLDI) experienced a remarkable surge, rising 119.7% in pre-market trading, reflecting significant investor interest and optimism in the company's innovative approach to cancer treatment.

Calidi Biotherapeutics has been actively developing a precision genetic medicine platform aimed at treating cancer through the precise delivery of genetic medicines. This innovative approach has garnered attention and support from investors, contributing to the recent surge in stock price.

The company recently announced the commencement of recruitment for a multiple-dose CLD-101 trial in patients with newly diagnosed high-grade glioma at Northwestern University Hospital. This clinical trial is a crucial step in validating the efficacy of Calidi's targeted antitumor virotherapy, which has the potential to revolutionize cancer treatment.

Additionally, Calidi Biotherapeutics has been proactive in securing funding through various public offerings and private placements. These financial maneuvers have bolstered the company's cash balance, providing the necessary resources to advance its research and development efforts. The termination of its standby equity purchase agreement further indicates the company's confidence in its financial stability and future prospects.

Overall, the recent developments and strategic initiatives by Calidi Biotherapeutics have positioned the company as a leader in the biotechnology sector, with a strong focus on innovative cancer treatments. The significant pre-market surge in stock price underscores the market's positive reception of these advancements and the potential for future growth.